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Abstract
Background: Colistin has a narrow therapeutic window with nephrotoxicity being the major dose-limiting adverse
effect. Currently, the optimal doses and therapeutic plasma levels are unknown.
Methods: Prospective observational cohort study, including patients infected by colistin-susceptible P. aeruginosa
treated with intravenous colistimethate sodium (CMS). Clinical data and colistin plasma levels at steady-state (Css)
were recorded. The primary and secondary end points were clinical cure and 30-day all-cause mortality.
Results: Ninety-one patients were included. Clinical cure was observed in 72 (79%) patients. The mean (SD)
Css was 1.49 (1.4) mg/L and 2.42 (1.5) mg/L (p = 0.01) in patients who achieved clinical cure and those who
not, respectively. Independent risk factors for clinical failure were male sex (OR 5.88; 95% CI 1.09–31.63),
APACHE II score (OR 1.15; 95% CI 1.03–1.27) and nephrotoxicity at the EOT (OR 9.13; 95% CI 95% 2.06–40.5).
The 30-day mortality rate was 30.8%. Risk factors for 30-day mortality included the APACHE II score (OR 1.98;
95% CI 1–1.20), the McCabe score (OR 2.49; 95% CI 1.14–5.43) and the presence of nephrotoxicity at the end
of treatment (EOT) (OR 3.8; 95% CI 1.26–11.47).
Conclusion: In this series of patients with infections caused by XDR P. aeruginosa infections, Css is
not observed to be related to clinical outcome.
Keywords: Colistin, Mortality, Plasma concentration, Pseudomonas aeruginosa, Extremely drug-resistant,
Nephrotoxicity
Background
The increasing incidence of infections due to multidrug-
resistant (MDR) gram-negative bacteria (GNB) is a con-
cern worldwide due to high morbidity and mortality [1]
and the lack of effective antimicrobials in the drug-
development pipeline [2]. Of particular concern are
MDR Pseudomonas aeruginosa, Acinetobacter baumannii
and Klebsiella pneumoniae [3]. For infections with these
organisms, the only therapeutic option may be colistin,
which was discovered in the 1940s but never subjected
to contemporary drug-development procedures. Colistin
exhibits concentration-dependent bacterial killing, and
its therapeutic efficacy depends on the ratio of the peak
level to the minimal inhibitory concentration (MIC) or
the area under the curve (AUC) to the MIC [4–6].
Colistin has a narrow therapeutic window, with nephro-
toxicity being the most important dose-limiting adverse
effect [4, 7]. Some non-comparative studies have re-
ported that colistin has an acceptable efficacy and safety
profile in the treatment of infections caused by MDR-
GNB [8–10]. However, lower success rates are shown
when compared with alternatives [11]. Although some
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clinical factors have been proposed as possible causes of
this lower success rate, one important issue in this sce-
nario is the shortage of available pharmacokinetic and
pharmacodynamic data to guide the proper use of colis-
tin in daily clinical practice [12].
Some recent studies have demonstrated that the current
colistimethate sodium (CMS) dosage regimens are associ-
ated with suboptimal colistin concentrations and subopti-
mal pharmacokinetic targets for many strains of GN-
GNB, and limited information is available regarding the
optimal doses and the levels of colistin in plasma that pro-
vides a therapeutic effect. In addition, to date, no clinical
studies have assessed the possible relationship between
plasma colistin concentrations and clinical outcome. The
aim of this study was to assess the possible relationship
between colistin plasma concentration (Css) and clinical
cure and 30-day all-cause mortality in patients with infec-
tions due to colistin-susceptible extremely drug-resistant
(XDR) P. aeruginosa who had been treated with intraven-
ous CMS. The presence of nephrotoxicity at the end of
treatment (EOT) was also analyzed.
Methods
Study population and data collection
A prospective observational cohort study was conducted
between January 2009 and January 2013 at a 450-bed
teaching hospital in Barcelona, Spain. All patients who
had microbiologically documented infections due to
colistin-susceptible XDR-P.aeruginosa and were admin-
istered CMS for at least 72 h, were included in the study.
Only microbiologically documented and clinically
defined infections caused by colistin-susceptible XDR
P. aeruginosa treated with colistin were considered.
Acute bronchitis and tracheitis were excluded from the
analysis due to the difficulty in differentiating true in-
fection from colonization in patients with chronic ob-
structive pulmonary disease (COPD).
Patients were identified through the hospital’s phar-
macy registry of antibiotic use. Patients were excluded if
they were < 18 years old, pregnant, breastfeeding, on
renal replacement therapy prior CMS treatment or if
they had received CMS treatment for less than 72 h.
Patients who after a cured infection episode received an-
other CMS curse due to another infection by XDR-P.
aeruginosa, were considered as 2 different cases.
Patients were followed until hospital discharge or death.
The ethical committee of the hospital (Comité Ètic de
Investigació Clínica del Parc de Salut Mar) approved the
study. Informed consent was obtained form all partici-
pating patients or their legal representatives.
A standardized form was used to record patient char-
acteristics, including age, sex, body weight, body mass
index, data on the indication for CMS, the CMS admin-
istration schedule, the daily CMS dose in millions of
international units (IU), the cumulative CMS dose (in
millions of IU), the duration of treatment and the colis-
tin plasma concentration at steady state (Css). Additional
clinical data collected for the study included the follow-
ing: baseline glomerular filtration rate (GFR), calculated
using the abbreviated Modification of Diet in Renal
Disease equation (MDRD) [13]; the presence of chronic
kidney disease (CKD) at baseline, which was diagnosed
when the GFR was < 60 mL/min/1.73 m2 for ≥ 3 months;
the presence of underlying comorbidities, evaluated by
the Charlson comorbidity index [14]; the severity of
disease at the time of the first CMS dose, stratified ac-
cording to the Acute Physiology and Chronic Health
Evaluation (APACHE II) [15]; concomitant nephrotoxic
drugs (aminoglycosides, vancomycin, nonsteroidal anti-
inflammatory drugs, intravenous radiocontrast agent,
loop diuretic, angiotensin-converting-enzyme inhibitors,
angiotension II receptor antagonist and ciclosporine);
the causative organism and in vitro susceptibility data;
the use of combined antibiotic treatment; and the clin-
ical response to therapy. Data were prospectively col-
lected for 30 days from the onset of CMS treatment,
unless otherwise specified.
The primary end point was clinical cure, and the sec-
ondary 30-day all-cause mortality.
Definitions and microbiological testing
Infections were defined according to the Centers for
Disease Control and Prevention (CDC) [16]. The pa-
tient’s clinical status at the beginning of CMS treatment
was defined as infection, severe sepsis or septic shock,
According to standard definitions [17], severe sepsis was
considered when an acute organ dysfunction secondary
to documented or suspected infection and septic shock
was defined as having a severe sepsis plus hypotension
not reversed with fluid resuscitation.
Clinical cure and failure were defined as resolution
and persistence/worsening, respectively, of symptoms
and signs of infection.
Thirty-day all-cause mortality was considered as death
during the hospitalization.
XDR-Pseudomonas aeruginosa was defined according to
the CDC/ECDC criteria [18] as an isolate non-susceptible
to at least 1 agent in all but 2 or fewer categories: aminogly-
cosides, antipseudomonal carbapenems, antipseudomonal
cephalosporins, antipseudomonal fluoroquinolones, anti-
pseudomonal penicillins + β-lactamase inhibitor, monobac-
tams, phosphonic acids and polymyxin.
Combined antibiotic treatment consisted of
CMS plus ceftazidime or carbapenem in high-dose ex-
tended infusion, or CMS plus amikacin.
Routine identification and susceptibility testing of causa-
tive microorganisms were first performed by microdilu-
tion using the gram-negative (GN) breakpoint panel for
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non-fermenting GNB of the MicroScan® WalkAway
system (Siemens Diagnostic Inc., CA). The colistin Min-
imal Inhibitory Concentration (MIC) was determined by
microdilution using cation-adjusted MHB; the isolates
were considered susceptible if the MIC value was < 2 mg/L
according to the Clinical and Laboratory Standards Insti-
tute (CLSI). Performance standards for antimicrobial
susceptibility testing; informational supplement. CLSI
document M100-SCLSI, Wayne, PA (2013).
CMS administration and colistin plasma level
measurements
CMS for injection was used and dosed in millions of IU
throughout the study. The drug was administered intra-
venously in 100 mL of normal saline over 30 min in the
commercially available colistimethate formulation for in-
jection (GES GenéricosEspañoles®), with each vial con-
taining 80 mg CMS (equivalent to 1 million IU of CMS
and about 30 mg of colistin base activity). As the policy
of our hospital, CMS is reserved for the treatment of
infections due to bacteria that are resistant to carbapen-
ems and other antipseudomonal antibiotics except colis-
tin and, eventually, aminoglycosides. Dose selection was
at the discretion of the responsible clinicians. CMS doses
ranged from 1 to 3 million IU every 8 h (3–9 millions
IU daily). The following dose adjustments were made ac-
cording to the package insert’s recommendations in pa-
tients with impaired renal function: GFR ≥ 76 mL/min/
1.73 m2, 4–6 million IU daily in three doses; GFR 40 to
75 mL/min/1.73 m2, 2–3 million IU daily in 2 doses;
GFR 25–40 mL/min/1.73 m2, 1.5–2 million IU daily di-
vided into 1 or 2 doses; and GFR < 25 mL/min/1.73 m2,
0.6–1 million IU daily every 36 h. No loading-dose was
administered to any included patient.
Measurement of the plasma colistin concentration was
performed at the fourth day of treatment, when was as-
sumed that the colistin concentrations had reached the
steady state. The colistin plasma trough concentrations
(Cmin) were measured just before the administration of
CMS. The maximum plasma concentrations (Cmax) were
obtained 30 min after the end of the CMS infusion (1 h
after the start of infusion). A specialized nurse per-
formed extraction of blood. Samples were immediately
placed in a portable refrigerator (4 °C) to be processed
in a refrigerated centrifuge (4 °C) at the laboratory.
Colistin concentrations in the plasma were determined
using a validated high-performance liquid chromatog-
raphy (HPLC) method as reportedby Li et al. [19], with
minor modifications as described previously by our
group [20].
Because the Cmax (1.66 ± 1.40 mg/L) and Cmin (1.71 ±
1.42 mg/L) were highly correlated (R = 0.98; P < 0.001),
only one of these variables was used throughout the
study as a marker of colistin plasma exposure. Following
Couet et al. [21], Cmin was chosen because it is more
convenient from a practical view point and because due
to the colistin pharmacokinetic behavior, there can be
CMS hydrolysis to colistinafter sample extraction result-
ing in an overestimation of the real in vivo colistin
plasma concentration. This phenomenon can be mini-
mized when CMS plasma concentrations are lower what
occurs at the end of the dosing interval (when the Cmin
is measured). Throughout the present paper, we have
used the term “average colistin concentration at steady
state (Css)” to refer to the Cmin.
Efficacy and nephrotoxicity assessment
Thirty-day mortality was defined as death occurring
within 30 days of beginning CMS treatment.
Clinical cure was defined as having resolved clinical
signs and symptoms and/or no need for additional anti-
biotic therapy. Clinical failure was defined as an inad-
equate response to antibiotic therapy, with worsening,
new/recurrent signs and symptoms or death.
The serum creatinine level and estimated glomerular
filtration rate (GFR) were recorded at baseline, at the
moment of colistin plasma extraction (day 4), on day 7
and at the EOT. We chose these time points because in
our center, blood tests are performed routinely in all
inpatients at least once a week and at the end of treat-
ment. The RIFLE criteria (Table 1) estimated with exclu-
sion of the urinary output criterion, were used for the
detection and stratification of acute kidney injury (AKI)
[22]. AKI during CMS treatment was defined as a 1.5-
fold or more increase in serum creatinine and/or a de-
crease in the GFR of 25% or more. These criteria needed
to be fulfilled for at least 2 consecutive measurements
24 h apart during CMS treatment.
Statistical analysis
Dichotomous data were compared using a χ2 or Fisher’s
exact test. Normally distributed continuous data are
expressed as the means with standard deviations (SD) and
were compared using the t-test. Otherwise, values are
Table 1 Definition of the RIFLE criteria to assess renal injury
Category criteria Definition
Risk (R) Increased creatinine level × 1.5 or 1
GFR decrease > 25%
Injury (I) Increased creatinine level × 2 or 1
GFR decrease > 50%
Failure (F) Increased creatinine level × 3, 1
GFR decrease > 75%, or creatinine
level > 4 mg/dL
Loss (L) Persistent acute renal failure or
loss of function for > 4 weeks
End-Stage Kidney Disease (ESKD) (E) ESKD for > 3 months
1 GFR glomerular filtration rate
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presented as the means with interquartile range (IQR) and
were compared using the Mann–Whitney U-test.
Logistic regression was used to explore risk factors
associated with clinical cure and 30-day all- cause
mortality.
Univariate analyses were performed separately for each
of the risk factor variables to ascertain the odds ratios
(ORs) and 95% confidence intervals (CI). For continuous
variables found significant in the analysis, the threshold
breakpoint was determined (Css). All clinically important
covariates and those with a P value < 0.2 in the univari-
ate analyses were included in the multivariate analysis.
Css was also analyzed and included in the model as a di-
chotomous variable by defining one set point. According
to Garonzik et al. [6], this set point was 1.25 mg/L, corre-
sponding to a target AUC0–24 of 60 mg.h/L for a P. aerugi-
nosa strain with an MIC value of 0.5 mg/L, which is the
predominant strain at our center.
A backward selection process was utilized in which
the results of the Wald test for individual parameters
were examined. The least significant effect that did not
meet the level for staying in the model was removed and
it remained excluded.
Multivariate logistic regression models were assessed
using the Hosmer–Lemeshow goodness-of-fit test. The
discriminatory power of the predictive model was estab-
lished by means of receiver operating characteristic
(ROC) curves. For all analyses, a two-sided P value
<0.05 was considered to be statistically significant. The
Statistical Package for the Social Sciences (SPSS, version
15.0) was used for the statistical analysis.
Results
During the study period, 124 patients with colistin-
susceptible XDR P. aeruginosa infections treated with
intravenous CMS were evaluated. Of these, 33 (26.6%)
were diagnosed with acute bronchitis or tracheitis and
were excluded. Thus, 91 patients were finally included in
the analysis. Three patients developed 2 infectious epi-
sodes due to XDR-P. aeruginosa (patient 1: two episodes
of UTI in 3 months. The second episode was considered
a new infection; patient 2: two episodes of UTI in
5 months. The second episode was considered a new
infection; patient 3: one episode of ventriculitis and one
UTI), and each infection was included as a separate case.
The clinical and demographic characteristics of the
included patients are shown in Table 2.
Clinical cure was observed in 72 (79.1%) patients.
Table 3 shows the clinical characteristics of patients with
clinical cure and clinical failure. The patients with
clinical failure were mainly men with higher APACHE II
indices. Additionally, they had achieved higher Css values
and were more likely to have developed AKI than
patients with clinical cure. In the multivariate analysis,
factors related to clinical failure were male sex (OR 5.88;
95% CI 1.09–31.63, P = 0.039), APACHE II score (OR
1.15; 95% CI 1.03–1.27, P = 0.013) and the presence
of AKI at the EOT (OR 9.13; 95% CI 95% 2.06–40.5,
P = 0.004).
Twenty eight patients died during hospitalization so
the 30-day all-cause mortality rate was 30.8%. However,
only 13 patients died due to P. aeruginosa infection lead-
ing to a infection-related mortality rate of 14.3%. These
data reveals that 15 out of the 28 patients who died
(53.6%) did so for reasons other than the infection itself.
Causes of death in these patients were mainly related to
their comorbid conditions (4 patients of COPD compli-
cations, 2 of cirrhosis, 2 of heart failure, 1 because
malignancy, 2 of hematological malignancies, 1 because
complications of Clostridium difficile infection) or post-
surgical complications (3 patients). So only one death in
this group could be related to colistin treatment and it
was one patient who died because a Clostridium difficile
infection. However, this patient has also been treated
with other antibiotics in addition to colistin. The pa-
tients who died were mainly men with higher Charlson,
APACHE II and McCabe scores, higher Css values and a
higher likeliness of having developed AKI during treat-
ment (Table 4). In the multivariate analysis, the follow-
ing independent risk factors for 30-day mortality were
identified: APACHE II score (OR 1.98; 95% CI 1–1.20,
P = 0.046), McCabe score (OR 2.49; 95% CI 1.14–5.43,
P = 0.021), and the presence of AKIat the EOT (OR 3.8;
95% CI 1.26–11.47, P = 0.018).
Twelve patients (13.2%) presented AKI prior CMS
treatment. This factor was not related with 30-day all-
cause mortality (P = 0,5) or clinical cure (P = 1). Impair-
ment of renal function during CMS treatment was ob-
served in 30 (33%) patients on day 7 and in 49 (53.8%)
at the EOT. The distribution of AKI on the basis of the
RIFLE criteria was 19 (20.9%) R, 9 (9.9%) I and 2 (2.2%)
F on day 7 of treatment; and 12 (13.2%) R, 27 (29.7%) I
and 10 (11%) F at the EOT. The CMS dose was modified
because of AKI in 16 (17.5%) patients. At the end of
follow-up, the GFR returned to baseline in 32 (35.1%)
patients. Two patients (2.1%) persisted with some grade
of impairment of renal function, 15 (16.4%) died and 3
(3.2%) patients had no follow-up information regarding
renal function.
Discussion
Currently, there is a lack of pharmacokinetic and phar-
macodynamic data to guide the proper use of colistin in
daily clinical practice. We have observed that Css is not
related to clinical cure and 30-day all-cause mortality in
a prospective series of patients infected with colistin-
susceptible XDR P. aeruginosa.
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Clinical cure in this series of patients was 79.1% and was
similar to those reported in previous studies [9, 10, 23–25].
Factors related with clinical failure were APACHE II
score and the presence of nephrotoxicity at the EOT.
We highlight the fact that colistin plasma levels were
not related with clinical cure. This finding is in some
disagreement with recent studies suggesting that higher
doses of CMS might be more appropriate for the treat-
ment of infections caused by MDR-GNB [6, 26, 27].
However, some recent clinical experiences did not ob-
serve a significant association between the CMS dose
and the clinical or microbiological outcomes. Yilmaz et
al. studied daily doses of 3 and 6 million IU CMS in the
treatment of infections caused by MDR-GNB and ob-
served no differences in the end points [28]. In another
study, Zaidi et al. reported that low CMS doses could
also be an effective option in the treatment of
infections caused by MDR-GNB [29]. The reasons for
this apparent lack of relationship between colistin con-
centrations or doses, and clinical outcome need to be
studied in depth in future studies.
In terms of PK analysis, data from the present study
are consistent with the results of these previous studies,
in the sense that the classic CMS dosage regimens are
associated with suboptimal colistin concentrations and
suboptimal pharmacokinetic targets for many strains of
GN-GNB. However, based on the population model
described by Garonzik et al. [6], we defined a set point
corresponding to a target AUC0–24 of 60 mg.h/L for a
Table 2 Clinical and demographic characteristics of included
patients
Included patients (n = 91)
Age, years* 67 (24–88)
Male sex, n (%) 66 (72.5)










Charlson score* 4 (0–10)
McCabe score** 1.48 ± 0.64
Patients with CKD1 at baseline 19 (20.9)
Type of infection, n (%):
Pneumonia 24 (24.6)
Urinary tract infection 22 (24.2)
Skin and soft tissue infection 11 (12.1)
Organ space surgical site infection 10 (11)
Bacteremia 6 (6.6)
Other 18 (19.8)









CMS3 daily dose (millions of IU4)** 5.45 ± 2.21
CMS3 total dose (millions of IU4)** 108.36 ± 96.41
CMS3 duration of treatment, days** 20.18 ± 16.01
Inhaled CMS3, n (%) 14 (15.4)
Combined antimicrobial therapy, n (%) 46 (50.5)
Css
5 (mg/L)** 1.67 ± 1.42
Css
5 > 1.28 (mg/L), n (%) 46 (50.5)
Css
5 /MIC6** 3.43 ± 2.91
AKI7 prior to CMS3 treatment, n (%) 12 (13.2)
Table 2 Clinical and demographic characteristics of included
patients (Continued)
Patients with AKI at day 7, n (%)
R (Risk) 19 (20.9)
I (Injury) 9 (9.9)
F (Failure) 2 (2.2)
Patients with AKI7 at the EOT8, n (%)
R (Risk) 12 (13.2)
I (Injury) 27 (27.7)
F (Failure) 10 (11)
Clinical response, n (%) 72 (79.1)
30-Day all-cause mortality, n (%) 28 (30)
Hospital length-of-stay (days)* 67 ± 53.97
1CKD chronic kidney disease, 2ICU intensive cure unit, 3CMS colistin
methanesulphonate, 4IU international units, 5Css colistin plasma concentration
at steady-state, 6MIC minimal inhibitory concentration, 7AKI acute kidney injury,
8EOT end of treatment
*median (range)
**mean ± SD
aAmong urogenital co-morbidities were, renal disease, kidney stones and
obstructive uropathy
bAmong haematological co-morbidities were haemopoietic and
lymphoreticular malignances
cAmong neurological co-morbidities were Alzheimer’s disease, stroke, miastenia
gravis, sclerosis and any kind of dementia
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Table 3 Clinical and demographic characteristics of patients
with and without clinical cure
Clinical cure Clinical failure P-value
(n = 72) (n = 19)
Male sex 49 (68) 17 (89.5) 0.06
Age, years* 66.5 (24–88) 67 (41–84) 0.59
APACHE II* 11 (2–28) 13.5 (6–24) 0.05
Co-morbidities, n (%):
Malignancy 11 (15.3) 3 (15.8) 1
Cardiovascular 21 (29.2) 5 (26.3) 1
Pulmonary 24 (33.3) 9 (47,4) 0,26
Diabetes Mellitus 20 (27.8) 1 (5.3) 0.06
Urogenitala 11 (15.3) 3 (15.8) 1
Hepatic 8 (11.1) 8 (0) 0.2
Haematologicalb 9 (12.5) 3 (15.8) 0.7
Neurologicalc 16 (22.2) 2 (10.5) 0.34
Charlson* 4.5 (0–10) 4 (1–9) 0.73
McCabe** 1.4 ± 0.6 1.7 ± 0.7 0.11
Severe sepsis, n (%) 49 (68.1) 9 (47.4) 0.095
Shock 6 (8.3) 1 (5.3) 0.65
Patients with CKD at baseline 16 (22.2) 3 (15.8) 0.53
Department of hospitalization:
Medical 38 (52.8) 6 (31.6) 0.16
Surgical 23 (32) 9 (47.4)
ICU2 11 (15.3) 4 (21.1)
Admission diagnosis category:
Infection 19 (26.4) 7 (36.8)
Other-medical 30 (41.7) 5 (26.3)
Other-surgical 23 (3.9) 7 (36.8) 0.45
CMS daily dose (millions IU)** 5.3 ± 2.3 6.2 ± 2.1 0.094
CMS total dose (millions IU)** 105.91 ± 88.9 141.2 ± 129.5 0.45
CMS duration of treatment, days** 20.66 ± 16.1 22.6 ± 18.5 0.81
Combined treatment, n (%) 35 (48.6) 11 (57.9) 0.47
Css (mg/mL)** 1.49 ± 1.4 2.42 ± 1.49 0.01
Css > 1.25 (mg/mL), n (%) 32 (45.1) 14 (73.7) 0.027
Css/MIC** 3.13 ± 2.9 4.61 ± 2.86 0.03
AKI at day 7, n (%) 18 (25) 12 (63.2) 0.002
AKI at the EOT, n (%) 33 (45.8) 16 (84.2) 0.003
Length of stay, days** 69.16 ± 59.5 70.8 ± 39.1 0.19
1CKD chronic kidney disease, 2ICU intensive cure unit, 3CMS colistin
methanesulphonate, 4IU international units, 5Css colistin plasma concentration
at steady-state, 6MIC minimal inhibitory concentration, 7AKI acute kidney injury,
8EOT end of treatment
*median (range)
**mean ± SD
aAmong urogenital co-morbidities were, renal disease, kidney stones and
obstructive uropathy
bAmong haematological co-morbidities were haemopoietic and
lymphoreticular malignances
cAmong neurological co-morbidities were Alzheimer’s disease, stroke, miastenia
gravis, sclerosis and any kind of dementia
Table 4 Clinical and demographic characteristics of patients






Male sex 24 (85.7) 42 (66.7) 0.06
Age, years* 66.85 (41–84) 65.5 (24–87) 0.12
APACHE II* 14 (5–27) 10.5 (2–28) 0.047
Co-morbidities, n (%):
Malignancy 6 (21.4) 8 (12.7) 0.35
Cardiovascular 7 (25) 19 (30.2) 0.8
Pulmonary 15 (53.6) 18 (28.6) 0.03
Diabetes Mellitus 3 (10.7) 18 (28.6) 0.1
Urogenitala 6 (21.4) 8 (12.7) 0.35
Hepatic 4 (14.3) 4 (6.3) 0.24
Haematologicalb 4 (14.3) 8 (12.7) 1
Neurologicalc 2 (7.1) 16 (23.4) 0.05
Charlson* 5 (1–9) 4 (0–10) 0.039
McCabe** 1.8 ± 0.7 1.3 ± 0.6 0.008
Clinical status, n (%)
Severe sepsis 15 (53.6) 43 (68.3) 0.17
Shock 2 (7.1) 5 (7.9) 0.89
Patients with CKD at baseline 7 (25) 12 (19) 0.52
Department of hospitalization:
Medical 12 (42.9) 32 (50.8)
Surgical 11 (39.3) 21 (33.3) 0.78
ICU2 5 (17.9) 10 (15.9)
Admission diagnosis category:
Infection 7 (25) 19 (30.2)
Other-medical 12 (42.9) 23 (36.5) 0.82
Other-surgical 9 (32.1) 21 (33.3)
CMS daily dose (millions IU)** 5.5 ± 2.4 5.4 ± 2.2 0.793
CMS total dose (millions IU)** 114.4 ± 116.5 113.3 ± 91.5 0.68
CMS duration of treatment, days** 20.3 ± 16.5 21.4 ± 16.6 0.88
Combined treatment, n (%) 15 (53.6) 31 (49.2) 0.7
Css (mg/L)** 2,1 ± 1.4 1.4 ± 1,4 0.011
Css > 1.25 (mg/L), n (%) 18 (64.3) 28 (44.4) 0.093
Css/MIC** 4.2 ± 2.7 3.1 ± 3 0.048
AKI at day 7, n (%) 14 (50) 16 (25.4) 0.021
AKI at the EOT, n (%) 20 (71.4) 29 (46) 0.025
Length of hospital stay, (days)** 65.2 ± 33.9 71.5 ± 63.2 0.3
1CKD chronic kidney disease, 2ICU intensive cure unit, 3CMS colistin
methanesulphonate, 4IU international units, 5Css colistin plasma concentration
at steady-state, 6MIC minimal inhibitory concentration, 7AKI acute kidney injury,
8EOT end of treatment
*median (range)
**mean ± SD
aAmong urogenital co-morbidities were, renal disease, kidney stones and
obstructive uropathy
bAmong haematological co-morbidities were haemopoietic and
lymphoreticular malignances
cAmong neurological co-morbidities were Alzheimer’s disease, stroke, miastenia
gravis, sclerosis and any kind of dementia
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P. aeruginosa with an MIC value of 0.5 mg/L, and this
set point was not related to the clinical outcomes or to
30-day all-cause mortality.
The 30-day all-cause mortality rate in our series was
30.9%. Previous comparative and non-comparative studies
have reported similar crude mortality rates [8, 11, 30, 31].
The APACHE II score and the severity of underlying
diseases have been previously reported as predictors of
mortality in patients treated with CMS for infections
caused by MDR-GNB [30]. In patients with ventilator-
associated pneumonia due to P. aeruginosa, the severity of
the clinical presentation has been reported to be the main
predictor of mortality [31]. In accordance with these stud-
ies, our series showed that the severity of the acute illness
and of the underlying diseases were also independent risk
factors for death.
An important finding of this study is that although Css
was not found to be a predictor of clinical failure or
mortality in the multivariate model, it is interesting that
Css was statistically significant in the univariate model
and that higher average Css values were associated to
clinical failure and also with 30-day all-cause mortal-
ity. In an attempt to address this finding, we analyzed
the ratio of discontinuation or doses adjustment of
colistin due to nephrotoxicity and there were no
differences between groups. In our opinion this fact
have to be studied in larger prospective studies but
one possible hypothesis is that higher levels of colistin
have been related to higher ratios of nephrotoxicity
[20] and maybe nephrotoxicity and not colistin levels
is the responsibly of this poor clinical outcome. In
fact, the presence of AKI at the EOT was related to
30-day all-cause mortality in a previous study carried
by our group [20].
Of note, in our series the presence of nephrotoxicity at
the EOT was associated with mortality and clinical
failure. Information about the impact of nephrotox-
icity during treatment with CMS on clinical out-
comes is scarce. The data that have been reported
are contradictory: although some studies have re-
ported higher rates of mortality in patients with
nephrotoxicity [8, 20], others have not found this as-
sociation [32, 33]. Our findings suggest that the de-
velopment of AKI during treatment with CMS seems
to be a more important dose-limiting adverse event
than previously recognized. According to our previ-
ously reported results showing rates of nephrotoxicity
of 65–85% with colistin trough concentrations
greater than 2.2 μg/mL [20], AKI during treatment
with CMS could be controlled by monitoring colistin
plasma concentrations.
We acknowledge some limitations of the current
study. First is its observational design that makes diffi-
cult to draw stronger conclusions. Second, the sample
was heterogeneous in terms of the infection source and
the administered CMS dose. In this scenario, previous
reports have demonstrated that patients with pneumonia
responded less favorably to CMS therapy [23, 34] prob-
ably due to the poor drug penetration to the epithelial
lining fluid. However this is a “real life” series with a
significant number of difficult to treat infections that
deserve to be studied in the antimicrobial resistance era.
Another limitation is that we did not use the loading
dose strategy because the protocol study was designed
before this practice was recommended in the literature.
Although recent published experiences have suggested
that this strategy has not been validated with clinical
data [32], without this loading dose it may be much lon-
ger to reach the steady-state. However colistin levels
were extracted at the fourth day of treatment and there-
fore analyses have been done at the steady state. Fourth
is the lack of specific analysis on the MICs of the
isolated microorganism in each patient. The efficacy of
antimicrobial therapy is not only based on drug expos-
ure or pathogen susceptibility, instead it is an integrated
function of both. The lack of this analysis is another
possible source of confounding and should be evalu-
ated in future studies. Aware of all these limitations
and with the intention of overcoming some of these
handicaps, our group has carried out a clinical trial
(clinicaltrials.gov number NCT01845246) whose results
are pending analysis and publication at this time.
Our findings highlight several issues. First, although it
is currently accepted that there is a need for changes in
the recommended CMS dosing regimens to achieve
higher colistin plasma levels [5, 6], in our study, the Css
was not related to a better clinical outcome. Second, our
results suggest that the severity of the infection, the
presence of comorbidities and the presence of AKI at
the EOT are the most important factors related to the
clinical outcome in XDR P. aeruginosa infections treated
with intravenous CMS. Third, because of these findings,
more prospective and homogeneous clinical studies
should be conducted to evaluate the benefit of monitor-
ing colistin concentrations in plasma in clinical practice.
These studies have to assess the issue of the optimal
dose of CMS in order to maximize clinical benefits and
minimize toxicities.
Conclusions
In conclusion in this series of patients, colistin plasma
levels were not observed to be related to clinical cure
or mortality in patients with XDR P. aeruginosa infec-
tions treated with CMS. However these finding needs
to be confirmed in future studies. Of note, the presence
of AKI at the EOT is a risk factor for mortality and
clinical failure.
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